{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T11:55:38Z","timestamp":1758282938469,"version":"3.44.0"},"reference-count":0,"publisher":"Sociedad Espanola de Quimioterapia","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev Esp Quimioter"],"published-print":{"date-parts":[[2025,9,15]]},"abstract":"<jats:p>Introduction: Dolutegravir plus lamivudine (DTG\/3TC) dual therapy has demonstrated efficacy in HIV treatment, but access remains challenging in Latin America. Argentina approved a generic co-packaged DTG+3TC presentation to improve accessibility. This study evaluated the effectiveness and safety of co-packed DTG\/3TC compared to DTG-based triple therapy in clinical practice. Materials and methods: A retrospective observational cohort study conducted between October 2019 and November 2023 at a reference HIV center in Argentina. Treatment-experienced people living with HIV (PLWH) with viral suppression who switched to either co-packaged DTG\/3TC or DTG-based triple therapy were included. Primary outcomes included persistence, virologic suppression rates (VSR), and safety at 6, 12, and 18 months. Results: Of 599 PLWH, 245 (41%) switched to dual therapy and 354 (59%) to triple therapy. Persistence rates for dual therapy at 6, 12, and 18 months were 99%, 100% and 98%; for triple therapy: 99%, 97% and 97%, respectively. VSR for dual therapy were 99%, 98% and 99%; for triple therapy: 99%, 97% and 98% at the same timepoints. Adverse event rates were low in both groups: dual therapy (0.5%, 0%, 0.8% at 6, 12, 18 months) and triple therapy (1.2%, 0.7%, 0.4% at 6, 12, 18 months). Conclusions: Co-packaged DTG\/3TC demonstrated high persistence and virologic suppression rates with a favorable safety profile in clinical practice. Its effectiveness and safety were comparable to DTG-based triple therapy, supporting its use as a cost-effective alternative for treatment-experienced PLWH in resource-limited settings.<\/jats:p>","DOI":"10.37201\/req\/030.2025","type":"journal-article","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T11:10:24Z","timestamp":1750072224000},"page":"386-393","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and safety of dual therapy with co-packaged dolutegravir and lamivudine compared to triple therapy as switching strategy in clinical practice"],"prefix":"10.37201","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8545-6132","authenticated-orcid":false,"given":"Diego","family":"Cecchini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0602-5175","authenticated-orcid":false,"given":"Edgardo","family":"Bottaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9543-2783","authenticated-orcid":false,"given":"Brenda","family":"Bacelar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4191-5094","authenticated-orcid":false,"given":"\u00c1ngeles","family":"Tisn\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7669-2552","authenticated-orcid":false,"given":"Claudia","family":"Migazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2952-1868","authenticated-orcid":false,"given":"Macarena","family":"Roel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3861-9196","authenticated-orcid":false,"given":"Maximiliano","family":"Bergman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4399-2628","authenticated-orcid":false,"given":"Isabel","family":"Cassetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"23328","published-online":{"date-parts":[[2025,6,16]]},"container-title":["Revista Espa\u00f1ola de Quimioterapia"],"original-title":[],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T08:31:53Z","timestamp":1758270713000},"score":1,"resource":{"primary":{"URL":"https:\/\/revespquimioterapia.com\/articulo\/effectiveness-and-safety-of-dual-therapy-with-co-packaged-dolutegravir-and-lamivudine-compared-to-triple-therapy-as-switching-strategy-in-clinical-practice"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,16]]},"references-count":0,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,9,15]]},"published-print":{"date-parts":[[2025,9,15]]}},"URL":"https:\/\/doi.org\/10.37201\/req\/030.2025","relation":{},"ISSN":["1988-9518","0214-3429"],"issn-type":[{"type":"electronic","value":"1988-9518"},{"type":"print","value":"0214-3429"}],"subject":[],"published":{"date-parts":[[2025,6,16]]}}}